A chirality switch in which the intrinsic chirality of a 4,4'-bipyridine is combined with a metal-ion-induced switching principle is described. In the uncomplexed state the 4,4'-bipyridine unit, which is linked to an S,S,S,S-configured cyclic imidazole peptide, is P-configured. The addition of zinc ions leads to a rotation around the C-C bond axis of the 4,4'-bipyridine and the M isomer of the metal complex is formed. By addition of a stronger complexing agent the metal ions are removed and the switch returns to its initial position. The combination of the chirality switch with a second switching unit allows the construction of a molecular pushing motor, which is driven chemically and by light.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/chem.201304166 | DOI Listing |
Curr Opin Infect Dis
January 2025
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.
Purpose Of Review: To discuss the new available options for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and how to implement in the clinical practice innovative approaches for their management.
Recent Findings: The availability of long-acting antibiotics, including dalbavancin and oritavancin, changed the approach to patients with ABSSSI. Direct discharge from the emergency department and early discharge from the hospital should be considered in patients with ABSSSI.
Lancet Microbe
January 2025
Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden. Electronic address:
Background: Antibiotic heteroresistance is a common bacterial phenotype characterised by the presence of small resistant subpopulations within a susceptible population. During antibiotic exposure, these resistant subpopulations can be enriched and potentially lead to treatment failure. In this study, we examined the prevalence, misclassification, and clinical effect of heteroresistance in Escherichia coli bloodstream infections for the clinically important antibiotics cefotaxime, gentamicin, and piperacillin-tazobactam.
View Article and Find Full Text PDFCancer Lett
January 2025
Department of Human Biology, University of Haifa, Haifa, Israel. Electronic address:
Metastatic breast cancer (BC) can recur years after initial treatments and arise from quiescent disseminated tumor cells (QDTC) that resist conventional therapies. To date there are no treatments to target QDTCs. Previously, the fibrotic-like niche (FLN) enriched with Type I collagen (Col-I) was shown to be required for the switch of QDTC to overt metastases.
View Article and Find Full Text PDFBreast
January 2025
Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy.
Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). Recently, the Italian Medicines Agency (AIFA) approved the possibility of switching between CDK4/6i for unacceptable toxicity.
View Article and Find Full Text PDFMult Scler Relat Disord
January 2025
Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy. Electronic address:
Background: There is increasing recognition Functional Neurological disorder (FND) is comorbid with other neurological conditions, but little is known about patients with Multiple Sclerosis (MS). We therefore systematically evaluated the presence of FND in consecutive patients with MS and its clinical correlates.
Methods: Three-hundred and ten consecutive MS patients, seen at our center on either elective or emergent basis, underwent a structured protocol to gather demographics and data about clinical features, previous and current treatments and presence of mood disorders and were additionally assessed by an expert in FND.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!